Metastatic volume: An old oncologic concept and a new prognostic factor for stage IV melanoma patients

Dermatology

Volumn 227, Issue 1, 2013, Pages 55-61

  Panasiti, V ^a   Curzio, M ^b   Roberti, V ^b   Lieto, P ^b   Devirgiliis, V ^b   Gobbi, S ^b   Naspi, A ^b   Coppola, R ^a   Lopez, T ^a   Di Meo, N ^c   Gatti, A ^c   Trevisan, G ^c   Londei, P ^b   Calvieri, S ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Distant metastases; Melanoma; Metastatic volume; Prognostic factor; Staging system; Survival time

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTINGENCY TABLE; DEATH; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC VOLUME; MIDDLE AGED; MULTICENTER STUDY; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR BURDEN;

EID: 84885600260     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000351713     Document Type: Article

References (25)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365: 687-701
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206
3. Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006; 355: 51-65
4. Neuman HB, Patel A, Ishill N, et al. A singleinstitution validation of the AJCC staging system for stage IV melanoma. Ann Surg Oncol 2008; 15: 2034-2041
5. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 2007; 33: 665-680
6. Seigler HF, Lucas VS Jr, Pickett NJ, Huang AT. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 1980; 46: 2346-2348
7. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66: 1873-1878
8. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64: 2024-2029
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
10. Schoonjans F, Zalata A, Depuydt CE, Comhaire FH. MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed 1995; 48: 257-262
11. Ackerman LV, Del Regato J. Cancer Diagnosis, Treatment and Prognosis. St Louis, Mosby, 1947, pp 169-181
12. McNeer G, Das Gupta T. Prognosis in malignant melanoma. Surgery 1964; 56: 512-518
13. American Joint Committee on Cancer Staging and End-Results Reporting: Staging of Malignant Melanoma. Manual for Staging of Cancer 1977. Chicago, American Joint Committee on Cancer, 1977, pp 131-140
14. Ketcham AS, Christopherson WO. A staging system for malignant melanoma. World J Surg 1979; 3: 271-278
15. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997; 15: 1039-1051
16. Unger JM, Flaherty LE, Liu PY, Albain KS, Sondak VK. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 2001; 91: 1148-1155
17. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1: 126-134
18. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71: 2995-3005
19. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16: 1103-1111
20. Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997; 79: 2345-2353
21. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000; 18: 3782-3793
22. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193-201
23. Panasiti V, Naspi A, Devirgiliis V, Curzio M, Roberti V, Curzio G, Gobbi S, Calvieri S, Londei P. Correlation between insulin-like growth factor binding protein-3 serum level and melanoma progression. J Am Acad Dermatol 2011; 64: 865-872
24. Rughani MG, Gupta A, Middleton MR. New treatment approaches in melanoma: current research and clinical prospects. Ther Adv Med Oncol 2013; 5: 73-80
25. Wilmott JS, Scolyer RA, Long GV, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology 2012; 1: 997-999